Practice & Policy
Environmental impact ratings that could drive positive environmental changes in the manufacture and use of pharmaceuticals
Amelia Cussans, Guy Harvey, Terry Kemple, Tracy Lyons, Mike Tomson and Angela Wilson
BJGP Open 2022; 6 (1): BJGPO.2021.0214. DOI: https://doi.org/10.3399/BJGPO.2021.0214
Amelia Cussans
1
Psychiatry Trainee, Central North West London NHS Trust Mental Health Centre, London, UK
Guy Harvey
2
Member of the RCPsych Planetary Health and Sustainability Committee. Consultant Psychiatrist, Cumbria Northumberland Tyne and Wear NHS Trust, Newcastle upon Tyne, UK
Terry Kemple
3
Royal College of General Practitioners National Representative for Sustainability, Climate Change and Green Issues, Lead for Green Impact for Health Toolkit, Executive member of UK Health Alliance for Climate Change, London, UK
Tracy Lyons
4
Medicines Optimisation Pharmacist, Directorate Sustainability Lead, Radiology & Pharmacy, University Hospital Dorset NHS Foundation Trust, Poole, UK
Mike Tomson
5
Retired GP, Sheffield, UK
Angela Wilson
6
Locum, Oxfordshire Clinical Commissioning Group, UK
In this issue
Environmental impact ratings that could drive positive environmental changes in the manufacture and use of pharmaceuticals
Amelia Cussans, Guy Harvey, Terry Kemple, Tracy Lyons, Mike Tomson, Angela Wilson
BJGP Open 2022; 6 (1): BJGPO.2021.0214. DOI: 10.3399/BJGPO.2021.0214
Jump to section
More in this TOC Section
Related Articles
Cited By...
Intended for Healthcare Professionals